LivingGLP1
Study S002285

A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT01392573
Acronym
DUAL™ II
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
DOUBLE
Status
COMPLETED
Enrollment
413
Start
2011-11-28
Primary completion
2012-10-01
Lead sponsor
Novo Nordisk A/S
Conditions
Diabetes; Diabetes Mellitus, Type 2
Interventions
DRUG:insulin degludec/liraglutide; DRUG:insulin degludec
Results posted
TRUE
Secondary identifiers
EUDRACT_NUMBER:2011-002336-72; OTHER:U1111-1121-4897

Registered primary outcomes

  • Change From Baseline in HbA1c (Glycosylated Haemoglobin) [Week 0, week 26]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0010237Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
Natale P, The Cochrane database of systematic reviews
2025Systematic reviewPMID 39963952DOIcites ClinicalTrials.gov:NCT01392573; registry reference DERIVED:39963952
R0007584EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
Lingvay I, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2019Randomized trialPMID 30383495DOIregistry reference RESULT:30383495
R0017641Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program.
Khunti K, Diabetes therapy : research, treatment and education of diabetes and related disorders
2017Other trialPMID 28332144DOIcites ClinicalTrials.gov:NCT01392573; registry reference BACKGROUND:28332144
R0018950Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
Ericsson Å, Applied health economics and health policy
2017Nonrandomized studyPMID 28063135DOIregistry reference BACKGROUND:28063135
R0020281A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
King AB, Diabetes technology & therapeutics
2017Randomized trialPMID 28282219DOIcites ClinicalTrials.gov:NCT01392573; registry reference RESULT:28282219
R0021084Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
Vilsbøll T, Clinical drug investigation
2016OtherPMID 26894800DOIregistry reference RESULT:26894800
R0018403Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
Buse JB, Diabetes care
2014Randomized trialPMID 25114296DOIregistry reference RESULT:25114296